Navigation Links
Peptide in Medical Technology

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... first candidate from the Company's Cationic Lytic peptide (CLYP(TM)) platform technology. EP-100 is a targeted membrane-disrupting peptide and is designed to selectively target luteinizing ... poster presentation entitled, "Targeted Oncolytic peptide for Treatment of Ovarian Cancers" at the American ...

FDA Submission of B-R-A-H-M-S MR-proANP Kryptor

... Kryptor Test. Atrial Natriuretic peptide (ANP) is predominantly produced in the atrium of ... and cardiovascular homeostasis. Although this peptide is unstable, the B-R-A-H-M-S-assay detects the ... fragment: the Mid-Regional pro-Atrial Natriuretic peptide (MR-proANP). In contrast to the mature peptide, ...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

... and weight-lowering actions of AC164209, a peptide hybrid linking a glucagon-like peptide-1 (GLP-1) ... 8. Corporate-sponsored symposium: "Emerging peptide Hormone Therapies for the Treatment of ... help healthcare providers understand the peptide hormone approach to the treatment of ....

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

... to the development of proprietary peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is ... inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

... the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune ... the development of our intellectual property in peptide copolymers, including PI-2301," stated Thomas P. ... diseases." PI-2301 is a second-generation peptide copolymer from a similar compound class as ...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

... bring worldwide rights to FIRAZYR (Icatibant), a peptide based therapeutic for HAE which has received a ... assets include Jerini Ophthalmic, Inc. and JPT peptide Technologies GmbH - Unanimous support from ... Age-related Macular Degeneration (AMD) and JPT peptide Technologies GmbH, ...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

... presented early clinical results from its PI-2301 peptide copolymer program at both the 17th Annual ENS ... SC administration of the second-generation peptide copolymer PI-2301. This study demonstrated ... PI-2301 is a second generation peptide copolymer from a similar compound class as ...

CureDM's Diabetes Therapy Achieves Major Development Milestone

... the native form. HIP is a 14-amino acid human peptide derived from a specific human gene responsible ... therapy was stopped. About HIP Human proIslet peptide (HIP) stimulates the differentiation ... Hospital campus in Wynnewood, PA, is developing peptide therapeutics using a platform that combines ...

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis ... convenience." PI-2301 is a second generation peptide copolymer from a similar compound class as ... been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown ...

Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

... and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis ... in early 2008. PI-2301 is a second generation peptide copolymer from a similar compound class as ... been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown ...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

... (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased the ... short amino acid sequence, the Carboxyl Terminal peptide (CTP). CTP occurs naturally in humans, and ... trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... analogs play a distinct biological role from the PTH (parathyroid hormone) peptide by activating different signaling responses--PTH regulates calcium ... same extent as PTH, highlighting differing therapeutic effects of the two peptide types on calcium and bone metabolism. About BA058 BA058 is ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... gamma interferon itself. The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as a herpes simplex virus (HSV) ...

Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data

... Replikins Ltd. ( www.replikins.com ) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the ... which is now ready for testing. It used the same approach to produce a peptide H5N1 (avian flu) vaccine that successfully blocked low path H5N1. It has ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... Syncria. Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology, and ... Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood-sugar ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... epitope linked to a T-cell binding ligand (TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the ... it would appear that the L.E.A.P.S.(TM) construct represents a chimeric peptide with bi-functional behavior. About CEL-SCI: CEL-SCI Corporation is ...

Treatment Corrects Severe Insulin Imbalance in Animal Studies

... or too high, resulting in diabetes. The new study makes use of a peptide (an amino acid compound) called exendin-(9-39) that blocks the action of a ... her study team expects to progress to a larger clinical trial. "If this peptide can be developed into a treatment for children with this common form of ...

Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients

... available in 2008. About CD-NP CD-NP is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated ... developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small ...

Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients

... About CD-NP Nile's lead compound, CD-NP, is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated ... developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small ...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

... the San Diego Convention Center, Room 2. PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva ... held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory ...

Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio

... either used alone or in combination with other anti-viral drugs. As peptide conjugates, anti-PE agents may be well-suited for use in some of these ... viruses and virus-infected cells. Using a biotin-conjugated form of the peptide drug duramycin, which is known to bind to PE, Dr. Soares and her ...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease

... demonstrated that this plaque inhibitory activity is still active when peptide fragments of rBChE are used, rather than the full length protein. This may ... corroborate earlier findings, and demonstrate that both rBChE and its peptide fragments could disrupt amyloid beta organization and potentially limit ...

Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity

... offer a patient-friendly product to promote weight loss." About PYY peptide YY is a naturally occurring hormone that is believed to function as a ... technologies. Nastech is creating technologies that enable the delivery of peptide and protein therapeutics without the requirement of an injection, which ...

Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure

... enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute ... and adverse outcomes. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and ...

Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure

... 65 years of age and an underserved medical condition." Atrial natriuretic peptide (ANP) is a naturally produced peptide hormone involved in regulation of ... of action is believed to relate to diminished affinity for the natriuretic peptide clearance receptor and increased resistance to the enzyme neutral ...

UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure

... at the BIO Investor Forum in San Francisco, CA. "The development of a peptide that has natriuretic and renal effects, with relatively little effect on ... Officer of Nile. About CD-NP CD-NP is a rationally-designed synthetic peptide designed to incorporate the optimal components of naturally occurring ...

Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure

... at the BIO Investor Forum in San Francisco, CA. "The development of a peptide that has natriuretic and renal effects, with relatively little effect on ... Officer of Nile. About CD-NP CD-NP is a rationally-designed synthetic peptide designed to incorporate the optimal components of naturally occurring ...

Raptor Pharmaceuticals Provides Update of Product Programs

... BBB. From these experiments, the team selected a lead candidate transport peptide called RAP-2s. In this second year, the team will continue to assess ... which describes their efforts to develop a readily-manufactured RAP-based peptide to act as a delivery vehicle to the liver. Raptor authors include Sara ...

Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference

... Chimeric peptide Vaccine Aims to Use Memory Imprint to Yield a Strong and ... will present new data regarding the Company's RECALL-VAX(TM) chimeric peptide vaccine technology at the 13th International Congress of Immunology on ...

Neurocrine Biosciences Presents Elagolix Data

... and analgesics (non-steroidal anti-inflammatory drugs) are often ineffective in controlling the symptoms of endometriosis. Likewise, while peptide gonadotropin-releasing hormone (GnRH) agonists such as Lupron(R) (leuprolide acetate) and Zoladex(R) (goserelin acetate) are highly effective in ...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

... patients) over 16 weeks. About Albiglutide Albiglutide is an investigational biological, injectable form of human GLP-1 - a peptide that acts throughout the body to help maintain normal blood sugar levels and to control appetite. Normally, GLP-1 levels rise during a meal to help ...

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

... -- Eli Lilly and Company (NYSE: LLY ) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes. These data will be presented as part of the American ...

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

... of agents have been associated with renal impairment, hypotension and adverse outcomes. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the ...

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

... groups was diarrhea, and diarrhea was the most common adverse event leading to discontinuation. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a ...

Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009

... study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... attributes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secreting adenomas (watery diarrhea). In addition, octreotide substantially reduces and in many cases can control growth hormone and/or ...

Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials

... that amyloid beta clumps together and eventually kills brain cells. Solanezumab binds specifically to soluble amyloid beta and thereby may draw the peptide away from the brain through the blood. In short-term clinical studies, solanezumab appeared to have dose-dependent effects on amyloid beta in blood ...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

... from blood and tissue studies for a large number of diseases from 50 different human tissues representing 60 diseases and contains over one million peptide sequences, mapped to approximately 15,000 genes, combined with over eight million SNPs and haplotypes. OGAP(R) oncology contains proteomic data on ...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

... throughout the 4-week treatment period. In both studies the most common adverse event was diarrhea. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a ...
Other Contents
(Date:8/21/2014)... (ANU) team has successfully replicated one of the crucial ... powered by sunlight which could manufacture hydrogen as a ... It is an exciting prospect to use them to ... Dr Kastoori Hingorani, from the ARC Centre of Excellence ... Biology. , Hydrogen offers potential as a zero-carbon replacement ...
(Date:8/20/2014)... 2014 George E. Fox, a John and Rebecca Moores ... (UH), was named a fellow in the International Society for ... Fox is one of four members two from the ... as fellows in 2014. Fellows are elected every three years, ... 500 members from more than 20 countries, the ISSOL includes ...
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
(Date:8/21/2014)... Irvine, CA (PRWEB) August 21, 2014 ... co-founder of American Corporate Health, was recently ... most influential professionals in the field of ... the National Workers’ Compensation and Occupational Medicine ... practitioners, including attorneys, physicians, nurses, case managers, ...
(Date:8/21/2014)... 2014 As part of a continuing ... (USP) has joined with the Alliance for Safe Online ... illegal online sale of medicines. , “Helping to ensure ... foods is a core mission for USP and an ... said Ronald T. Piervincenzi, chief executive officer of USP. ...
(Date:8/21/2014)... August 21, 2014 According to a ... Fiber Optics Market-Global Industry Analysis, Size, Share, Growth, Trends ... optics market was valued at USD 863.1 million in ... of 7.6% from 2013 to 2019, to reach an ... The medical fiber optics market is witnessing significant growth ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... "Fundus Cameras Market - Global Industry Analysis, Size, Share, ... fundus cameras market was valued at USD 236.1 million ... worth USD 358.3 million in 2018 at a CAGR ... full Fundus Cameras Market Report: http://www.transparencymarketresearch.com/fundus-cameras.html . , ...
(Date:8/21/2014)... 21, 2014 The worlds of personal ... an exciting chance to grab free products. BaliniSports ... from Tom's of Maine with all qualifying purchases for ... our environmentally friendly yoga apparel is simply perfect,” said ... promotion between the two brands is intended to give ...
Breaking Medicine News(10 mins):Health News:Dr. Vasili Gatsinaris Named One of the Top 50 Most Influential in Workers’ Compensation 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2
Other TagsOther Tags